Jcr Pharmaceuticals
JCR Pharmaceuticals Co., Ltd., commonly referred to as JCR Pharma, is a leading biopharmaceutical company headquartered in Japan. Established in 2003, the company has made significant strides in the development of innovative therapies, particularly in the fields of rare diseases and regenerative medicine. With a strong focus on enzyme replacement therapies and gene therapies, JCR Pharma is renowned for its unique products that address unmet medical needs. The company operates primarily in Japan, with expanding influence in international markets. Notable achievements include the successful launch of its flagship products, which have positioned JCR Pharma as a key player in the biopharmaceutical industry. Through its commitment to research and development, JCR Pharmaceuticals continues to enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Jcr Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jcr Pharmaceuticals's score of 46 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jcr Pharmaceuticals's reported carbon emissions
In 2023, JCR Pharmaceuticals reported total carbon emissions of approximately 15,059,600 kg CO2e for Scope 1, 4,659,900 kg CO2e for Scope 2, and a significant 14,255,621,000 kg CO2e for Scope 3 emissions. The combined total for Scope 1 and 2 emissions was about 74,991,000 kg CO2e. Notably, the Scope 3 emissions, which encompass a wide range of activities including purchased goods and services (approximately 13,426,666,000 kg CO2e) and end-of-life treatment of sold products (approximately 581,582,000 kg CO2e), represent the largest portion of their carbon footprint. In 2022, JCR Pharmaceuticals' emissions were recorded at approximately 14,215,700 kg CO2e for Scope 1 and 9,418,700 kg CO2e for Scope 2, with no Scope 3 data disclosed for that year. The company has set near-term climate commitments, aiming to analyse risks and enhance information disclosure related to climate change in line with TCFD recommendations. These initiatives include calculating greenhouse gas emissions across their entire supply chain, specifically targeting reductions in Scope 1 and Scope 2 emissions from 2023 to 2025. JCR Pharmaceuticals is committed to transparency and accountability in its climate strategy, although specific reduction targets in terms of percentage have not been disclosed. The company is actively working towards achieving net-zero emissions, reflecting a growing commitment to sustainability within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 32,573,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,959,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jcr Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
